The Motley Fool
22 Oct 2026, 20:49 UTC · 1h ago
Great News for AbbVie Stock Investors
Impact · against what's priced in
The Phase 2a results for ABBV-466 provide a potential revenue bridge to mitigate the 2033 patent cliff, which the market is currently discounting. Other mentioned drivers, such as Skyrizi's growth and the Apogee acquisition, are already fully baked into the current stock price.
- ABBV+0.40
Challenges what's priced in
- The price assumes
The full upside of the immunology pipeline beyond current SKYRIZI and RINVOQ trajectories
The price currently ignores immunology pipeline upside beyond existing blockbusters; Phase 2a results for ABBV-466 showing superior remission rates to Skyrizi in Crohn's disease provide a concrete path to sustaining growth beyond the 2033 patent cliff.
What ABBV's price assumes · Sep 4
Search tags
